At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
VSJ-110 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Allergic Conjunctivitis Using an Allergen Challenge Model
In Brief
A Phase 2 clinical trial evaluating VSJ-110 and Placebo for Allergic Conjunctivitis. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionMay 2021
Study CompletionJun 2021
TodayJul 2026
First PostedNov 9, 2020
Enrollment StartNov 21, 2020
Primary CompletionMay 22, 2021
Study CompletionJun 28, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.6 years ago
Interventions
VSJ-110drug
ophthalmic solution
Placebodrug
ophthalmic solution